| MeSH term | MeSH ID | Detail |
|---|---|---|
| Bacterial Infections | D001424 | 21 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Lupus Erythematosus, Systemic | D008180 | 43 associated lipids |
| Stomach Diseases | D013272 | 7 associated lipids |
| Lung Diseases | D008171 | 37 associated lipids |
| Lung Neoplasms | D008175 | 171 associated lipids |
| Skin Neoplasms | D012878 | 12 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Leishmaniasis, Visceral | D007898 | 13 associated lipids |
| Diabetes Mellitus, Type 1 | D003922 | 56 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Zullo A et al. | A new highly effective short-term therapy schedule for Helicobacter pylori eradication. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848654 |
| Moayyedi P et al. | The effectiveness of omeprazole, clarithromycin and tinidazole in eradicating Helicobacter pylori in a community screen and treat programme. Leeds Help Study Group. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848655 |
| Katelaris PH et al. | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848659 |
| Ammon S et al. | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848660 |
| Leiper K et al. | Open label trial of oral clarithromycin in active Crohn's disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10848665 |
| Gisbert JP et al. | Systematic review: Rabeprazole-based therapies in Helicobacter pylori eradication. | 2003 | Aliment. Pharmacol. Ther. | pmid:12641497 |
| Perri F et al. | Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadruple therapy? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421877 |
| Wong WM et al. | Randomized controlled study of rabeprazole, levofloxacin and rifabutin triple therapy vs. quadruple therapy as second-line treatment for Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12622764 |
| Perri F et al. | Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421878 |
| Pilotto A et al. | Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421879 |
| Fischbach L and Evans EL | Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17635369 |
| Tepes B et al. | Is a one-week course of triple anti-Helicobacter pylori therapy sufficient to control active duodenal ulcer? | 2001 | Aliment. Pharmacol. Ther. | pmid:11421880 |
| Calvet X et al. | What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. | 2001 | Aliment. Pharmacol. Ther. | pmid:11421884 |
| Cardenas VM et al. | Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. | 2006 | Aliment. Pharmacol. Ther. | pmid:16393310 |
| Huang J et al. | Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study. | 2013 | Aliment. Pharmacol. Ther. | pmid:24117692 |
| Molina-Infante J et al. | Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication. | 2010 | Aliment. Pharmacol. Ther. | pmid:20180787 |
| Chacko Y and Holtmann GJ | Helicobacter pylori eradication and weight gain: has it opened a Pandora's box? | 2011 | Aliment. Pharmacol. Ther. | pmid:21679208 |
| Kamada T et al. | The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12869086 |
| Murakami K et al. | Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance. | 2003 | Aliment. Pharmacol. Ther. | pmid:12492740 |
| Gisbert JP et al. | 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882246 |
| Nista EC et al. | Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. | 2005 | Aliment. Pharmacol. Ther. | pmid:15882245 |
| Logan RP et al. | Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:8527618 |
| Lai KC et al. | Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535877 |
| Miehlke S et al. | Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. | 2006 | Aliment. Pharmacol. Ther. | pmid:16842467 |
| Boixeda D et al. | Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection. | 2002 | Aliment. Pharmacol. Ther. | pmid:12182745 |
| Gisbert JP et al. | Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10540045 |
| Lehmann FS et al. | Effect of ornidazole and clarithromycin resistance on eradication of Helicobacter pylori in peptic ulcer disease. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735923 |
| Miwa H et al. | Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. | 2000 | Aliment. Pharmacol. Ther. | pmid:10735925 |
| Veldhuyzen Van Zanten S et al. | One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12786632 |
| Lane JA et al. | Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. | 2011 | Aliment. Pharmacol. Ther. | pmid:21366634 |
| Laine L | Review article: esomeprazole in the treatment of Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:12047270 |
| Molina-Infante J et al. | Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study. | 2015 | Aliment. Pharmacol. Ther. | pmid:25776067 |
| Sasaki A et al. | Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. | 2003 | Aliment. Pharmacol. Ther. | pmid:12823156 |
| Khurana R et al. | Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. | 2007 | Aliment. Pharmacol. Ther. | pmid:17305754 |
| Pipkin GA et al. | Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768524 |
| Louw JA et al. | Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768531 |
| Laine L et al. | Low rate of emergence of clarithromycin-resistant Helicobacter pylori with amoxycillin co-therapy. | 1998 | Aliment. Pharmacol. Ther. | pmid:9768532 |
| Gu Q et al. | Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin. | 2004 | Aliment. Pharmacol. Ther. | pmid:15352916 |
| Wong WM et al. | One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929398 |
| Azuma T et al. | Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. | 2000 | Aliment. Pharmacol. Ther. | pmid:10807427 |
| Talley NJ et al. | Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678811 |
| Shokri-Shirvani J et al. | Letter: global emergence of Helicobacter pylori antibiotic resistance - unanswered questions. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137738 |
| Ricciardiello L et al. | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678812 |
| Cammarota G et al. | One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678813 |
| Louw JA et al. | Two-week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678814 |
| Axon AT et al. | Ranitidine bismuth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042977 |
| Ahuja V et al. | Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678815 |
| Labenz J et al. | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042978 |
| Grübel P and Cave DR | Factors affecting solubility and penetration of clarithromycin through gastric mucus. | 1998 | Aliment. Pharmacol. Ther. | pmid:9678818 |
| Labenz J et al. | Efficacy and tolerability of a one-week triple therapy consisting of pantoprazole, clarithromycin and amoxycillin for cure of Helicobacter pylori infection in patients with duodenal ulcer. | 1997 | Aliment. Pharmacol. Ther. | pmid:9042979 |
| Calvet X et al. | One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:12144575 |
| Di Caro S et al. | Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876707 |
| Wu JC et al. | Effect of Helicobacter pylori eradication on oesophageal acid exposure in patients with reflux oesophagitis. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876709 |
| Yousfi MM et al. | One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8853767 |
| Mason J et al. | The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876711 |
| Georgopoulos SD et al. | Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876712 |
| Elizalde JI et al. | Influence of Helicobacter pylori infection and eradication on blood lipids and fibrinogen. | 2002 | Aliment. Pharmacol. Ther. | pmid:11876713 |
| Hawkey CJ et al. | Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. | 2003 | Aliment. Pharmacol. Ther. | pmid:12694089 |
| Savarino V et al. | Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:9892878 |
| Furuta T et al. | Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. | 2007 | Aliment. Pharmacol. Ther. | pmid:17697203 |
| Wong BC et al. | Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. | 2001 | Aliment. Pharmacol. Ther. | pmid:11736727 |
| Goddard AF et al. | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233187 |
| Pilotto A et al. | The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10233191 |
| Wong BC et al. | Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa. | 2000 | Aliment. Pharmacol. Ther. | pmid:11069326 |
| O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
| Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
| Sheu BS et al. | The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755841 |
| Kim YS et al. | Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. | 2011 | Aliment. Pharmacol. Ther. | pmid:21923713 |
| Cammarota G et al. | Helicobacter pylori eradication using one-week low-dose lansoprazole plus amoxycillin and either clarithromycin or azithromycin. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971300 |
| Pilotto A et al. | Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971305 |
| Gudjonsson H et al. | High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate. | 1998 | Aliment. Pharmacol. Ther. | pmid:9845401 |
| De Francesco V et al. | Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113366 |
| Koivisto TT et al. | Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population. | 2004 | Aliment. Pharmacol. Ther. | pmid:15113368 |
| Gisbert JP and Calvet X | Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. | 2011 | Aliment. Pharmacol. Ther. | pmid:22017749 |
| Vakil N et al. | Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. | 2006 | Aliment. Pharmacol. Ther. | pmid:16803603 |
| Pellegrini M et al. | Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study. | 2005 | Aliment. Pharmacol. Ther. | pmid:16098001 |
| Vcev A et al. | Pantoprazole, amoxycillin and either azithromycin or clarithromycin for eradication of Helicobacter pylori in duodenal ulcer. | 2000 | Aliment. Pharmacol. Ther. | pmid:10632647 |
| Graham DY et al. | Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102946 |
| Zanten SJ et al. | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102960 |
| Pilotto A and Malfertheiner P | Review article: an approach to Helicobacter pylori infection in the elderly. | 2002 | Aliment. Pharmacol. Ther. | pmid:11929385 |
| Van der Wouden EJ et al. | The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102961 |
| Wong BC et al. | Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102962 |
| Perri F et al. | Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'. | 2003 | Aliment. Pharmacol. Ther. | pmid:14535875 |
| Xiao SD et al. | High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102963 |
| Laine L et al. | A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. | 1997 | Aliment. Pharmacol. Ther. | pmid:9354200 |
| Liu WZ et al. | Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102964 |
| Huang J and Hunt RH | Clarithromycin-based triple therapies. | 1999 | Aliment. Pharmacol. Ther. | pmid:10102978 |
| Xiao SD et al. | A multicentre study on eradication of Helicobacter pylori using four 1-week triple therapies in China. | 2001 | Aliment. Pharmacol. Ther. | pmid:11136281 |
| Sheu BS et al. | Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. | 2005 | Aliment. Pharmacol. Ther. | pmid:15691303 |
| Jung YS et al. | Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. | 2017 | Aliment. Pharmacol. Ther. | pmid:28497487 |
| Tsuzuki T et al. | Clarithromycin increases the release of heat shock protein B from Helicobacter pylori. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966545 |
| Gisbert JP et al. | Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. | 2012 | Aliment. Pharmacol. Ther. | pmid:22372560 |
| Ellenrieder V et al. | Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori. | 1998 | Aliment. Pharmacol. Ther. | pmid:9701524 |
| Lim AG et al. | Helicobacter pylori eradication using a 7-day regimen of low-dose clarithromycin, lansoprazole and amoxycillin. | 1997 | Aliment. Pharmacol. Ther. | pmid:9218079 |
| Nista EC et al. | Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. | 2004 | Aliment. Pharmacol. Ther. | pmid:15569121 |
| Zullo A et al. | Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? | 2010 | Aliment. Pharmacol. Ther. | pmid:20518756 |
| Armuzzi A et al. | The effect of oral administration of Lactobacillus GG on antibiotic-associated gastrointestinal side-effects during Helicobacter pylori eradication therapy. | 2001 | Aliment. Pharmacol. Ther. | pmid:11148433 |
| Harris AW et al. | Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. | 1996 | Aliment. Pharmacol. Ther. | pmid:8971302 |
| Mégraud F and Lamouliatte H | Review article: the treatment of refractory Helicobacter pylori infection. | 2003 | Aliment. Pharmacol. Ther. | pmid:12786627 |
| Graham DY et al. | Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. | 2003 | Aliment. Pharmacol. Ther. | pmid:12755836 |